Rapport Therapeutics Q3 2026 Earnings Date & Estimates

Rapport Therapeutics (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system.

Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy. The company is also advancing additional discovery and preclinical programs intended to address other nervous system conditions, with a focus on developing selective treatments that may offer improved efficacy and tolerability compared with less targeted approaches.

Rapport Therapeutics was established to apply receptor-associated protein biology to drug discovery and is headquartered in Boston, Massachusetts. Its development efforts are directed primarily toward neurological and psychiatric diseases affecting patients in global markets. Information about the company’s leadership and broader commercial operations is limited because Rapport remains focused on clinical development rather than marketing approved products.